LEAP THERAPEUTICS INC (LPTX) Stock Price, Quote, News and Overview
NASDAQ:LPTX - Nasdaq - US52187K2006 - Common Stock - Currency: USD
LPTX Quote, Performance and Key Statistics
0.4633
0 (-0.04%)
The current stock price of LPTX is 0.4633 USD. In the past month the price decreased by -10.78%. In the past year, price decreased by -83.63%.
LPTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.66 | 369.39B | ||
| AMGN | AMGEN INC | 15.54 | 165.43B | ||
| GILD | GILEAD SCIENCES INC | 24.8 | 142.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.39B | ||
| ARGX | ARGENX SE - ADR | 242.12 | 37.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 29.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.07B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| BIIB | BIOGEN INC | 8.53 | 20.47B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.26B |
Related stock screener links
About LPTX
Company Profile
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. The company also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Company Info
LEAP THERAPEUTICS INC
47 Thorndike St Ste B1-1
Cambridge MASSACHUSETTS 02141 US
CEO: Douglas E. Onsi
Employees: 54
Company Website: https://www.leaptx.com/
Investor Relations: https://investors.leaptx.com/
Phone: 16172524343
LEAP THERAPEUTICS INC / LPTX FAQ
What is the stock price of LEAP THERAPEUTICS INC today?
The current stock price of LPTX is 0.4633 USD. The price decreased by -0.04% in the last trading session.
What is the ticker symbol for LEAP THERAPEUTICS INC stock?
The exchange symbol of LEAP THERAPEUTICS INC is LPTX and it is listed on the Nasdaq exchange.
On which exchange is LPTX stock listed?
LPTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEAP THERAPEUTICS INC stock?
9 analysts have analysed LPTX and the average price target is 2.17 USD. This implies a price increase of 367.84% is expected in the next year compared to the current price of 0.4633. Check the LEAP THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEAP THERAPEUTICS INC worth?
LEAP THERAPEUTICS INC (LPTX) has a market capitalization of 17.75M USD. This makes LPTX a Nano Cap stock.
How many employees does LEAP THERAPEUTICS INC have?
LEAP THERAPEUTICS INC (LPTX) currently has 54 employees.
What are the support and resistance levels for LEAP THERAPEUTICS INC (LPTX) stock?
LEAP THERAPEUTICS INC (LPTX) has a resistance level at 0.48. Check the full technical report for a detailed analysis of LPTX support and resistance levels.
Should I buy LEAP THERAPEUTICS INC (LPTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LPTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LPTX, evaluating the profitability, health, valuation and growth aspects
- LEAP THERAPEUTICS INC (LPTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEAP THERAPEUTICS INC (LPTX) Sales and EPS estimates to see what analysts future expectations are.
- LEAP THERAPEUTICS INC (LPTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEAP THERAPEUTICS INC (LPTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEAP THERAPEUTICS INC (LPTX) Stock Chart to make your own analysis
- LEAP THERAPEUTICS INC (LPTX) Latest news and press-releases to stay up to date.
Does LEAP THERAPEUTICS INC (LPTX) stock pay dividends?
LPTX does not pay a dividend.
When does LEAP THERAPEUTICS INC (LPTX) report earnings?
LEAP THERAPEUTICS INC (LPTX) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of LEAP THERAPEUTICS INC (LPTX)?
LEAP THERAPEUTICS INC (LPTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
What is the Short Interest ratio of LEAP THERAPEUTICS INC (LPTX) stock?
The outstanding short interest for LEAP THERAPEUTICS INC (LPTX) is 10.12% of its float. Check the ownership tab for more information on the LPTX short interest.
LPTX Technical Analysis
LPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LPTX. The financial health of LPTX is average, but there are quite some concerns on its profitability.
LPTX Financial Highlights
Over the last trailing twelve months LPTX reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS increased by 65.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.66% | ||
| ROE | -132.42% | ||
| Debt/Equity | 0 |
LPTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to LPTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.